<DOC>
	<DOCNO>NCT00000640</DOCNO>
	<brief_summary>To evaluate effectiveness two oral treatment mild moderate Pneumocystis carinii pneumonia ( PCP ) : dapsone/trimethoprim clindamycin/primaquine compare standard treatment program sulfamethoxazole/trimethoprim ( SMX/TMP ) ass tolerance two alternative treatment compare standard treatment SMX/TMP . Per 09/09/92 amendment , ass efficacy tolerance two alternative treatment patient intolerant SMX/TMP . The type treatment study advantage wide applicability throughout world ( include develop country ) low cost . An oral treatment accessible patient drug give injection inhalation .</brief_summary>
	<brief_title>A Phase III Comparative Study Dapsone / Trimethoprim Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim Treatment Mild-to-Moderate PCP Patients With AIDS</brief_title>
	<detailed_description>The type treatment study advantage wide applicability throughout world ( include develop country ) low cost . An oral treatment accessible patient drug give injection inhalation . Patients confirm PCP randomize one three treatment group . Group A receive SMX/TMP . Half group A receive dapsone placebo ( placebo inactive substance ) daily plus trimethoprim placebo ; half receive clindamycin placebo plus primaquine placebo . Group B give dapsone plus trimethoprim . Half group B receive SMX/TMP placebo ; half receive clindamycin placebo plus primaquine placebo . Group C give clindamycin plus primaquine . Half group C receive SMX/TMP placebo , half receives dapsone placebo plus trimethoprim placebo . Treatment last 21 day ; dosage adjust patient weigh less 50 kg 80 kg . Patients history intolerance SMX/TMP rechallenge consider medically contraindicate may randomize one non-sulfamethoxazole-containing arm .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Erythropoietin . Maintenance treatment investigational triazoles ( e.g. , itraconazole ) . Antiemetics nausea/vomiting , antihistamine rash/pruritus , antipyretic systemic symptom ( fever , headache , etc . ) use treatment symptom . Nonsteroidal antiinflammatory agent may use control myalgia , headache , etc . Concurrent Treatment : Allowed : Blood transfusion . Patients must follow : Pneumocystis carinii pneumonia . HIV infection . Willing able sign inform consent . Patients 18 year age may enter consent parent guardian . Prior Medication : Allowed : Up 24 hour treatment sulfamethoxazole/trimethoprim ( SMX/TMP ) , dapsone / trimethoprim , clindamycin / primaquine , one dose pentamidine episode Pneumocystis carinii pneumonia ( PCP ) . Prior PCP prophylaxis . Required : Adjunctive prednisone therapy patient ( Aa ) DO2 35 45 torr receive acute antiPCP treatment . Exclusion Criteria Coexisting Condition : Patients follow condition disease exclude : Positive screen glucose6phosphate dehydrogenase deficiency . Known NAD methemoglobin reductase deficiency and/or know hemoglobin M abnormality . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Ganciclovir . GMCSF GCSF . Rifampin . Rifabutin . Corticosteroids ( patient baseline ( Aa ) DO2 &lt; 35 torr ) . Investigational drug specifically allow . Folinic acid . Patients follow exclude : Previous doselimiting intolerance sulfones , trimethoprim , clindamycin , primaquine . Requirement medication potentially effective treatment Pneumocystis carinii pneumonia ( PCP ) ( e.g. , pyrimethamine sulfadiazine ) . Prior enrollment ACTG 108 . Presence concurrent pulmonary pathology would make interpretation response antipneumocystis therapy difficult . Inability take oral therapy . Prior Medication : Excluded : Acute treatment dos antiPneumocystis carinii pneumonia agent within 30 day prior study entry except note . Systemic steroid adrenal replacement dos within 7 day prior study entry ( except patient ( Aa ) DO2 35 45 torr receive prednisone conjunction acute antiPCP treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clindamycin</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>